Abstract: The present invention relates to a composition for dyeing keratin fibres, comprising: a) one or more liquid fatty substances; b) one or more amphoteric surfactants of formula (I) below: Ra?-C(0)—NH—CH2—(CH2)n—N(B)(B?)(I) in which: B represents the group —CH2—CH2—O—X?; B? represents the group —(CH2)ZY?< with z=1 or 2; X? represents the group —CH2—C(O)OH, —CH2—C(O)OZ?, —CH2—CH2—C(O)OH or —CH2—CH2—C(O)OZ?, or a hydrogen atom; Y? represents the group —C(O)OH, —C(O)OZ?, —CH2—CH(OH)—S03H or the group —CH2-CH(OH)—S03-Z?; Z? and Z? represent, independently of each other, a cationic counterion derived from an alkali metal or alkaline-earth metal, such as sodium, an ammonium ion or an ion derived from an organic amine; Ra? represents a C10-C30 alkyl or alkenyl group derived from an acid Ra?—C(O)OH, which is preferably present in copra oil or in hydrolysed linseed oil, an alkyl group, especially a C17 group and its iso form, or an unsaturated C17 group and n represents an integer ranging from 1 to 10 and preferably f

Abstract: The present invention relates to a composition for dyeing keratin fibres, comprising: a) one or more liquid fatty substances; b) one or more amphoteric surfactants of formula (I) below: Ra—C(O)—NH—CH2—(CH2)n—N(B)(B?); in which: B represents the group —CH2—CH2—O—X?; B? represents the group —(CH2)zY?, with z=1 or 2; X? represents the group —CH2—C(O)OH, —CH2—C(O)OZ?, —CH2—CH2—C(O)OH or —CH2—CH2—C(O)OZ?, or a hydrogen atom; Y? represents the group —C(O)OH, —C(O)OZ?, —CH2—CH(OH)—SO3H or the group —CH2—CH(OH)—SO3—Z?; Z? and Z? represent, independently of each other, a cationic counterion derived from an alkali metal or alkaline-earth metal, such as sodium, an ammonium ion or an ion derived from an organic amine; Ra? represents a C10-C30 alkyl or alkenyl group derived from an acid Ra?—C(O)OH, which is preferably present in copra oil or in hydrolysed linseed oil, an alkyl group, especially a C17 group and its iso form, or an unsaturated C17 group and n represents an integer ranging from 1 to 10 and preferably from 1

Abstract: A cosmetic or dermatological antiperspirant composition which includes, based on the weight of the composition: a) at least one antiperspirant active ingredient, b) 0-5 wt. % of taurine, c) 0-5 wt. % of glycine, d) 0-5 wt. % of ectoine, e) 0-2 wt. % ethylene diamine tetra acetic acid and/or the salts thereof, f) 0-2 wt. % of ethylenediaminedisuccinic acid and/or the salts thereof, g) 0-2 wt. % of citric acid and/or the salts thereof, h) 0-2 wt. % of gluconic acid and/or the salts thereof, i) 0-2 wt. % of zeolite A, j) 0-2 wt. % of sodium tripolyphosphate, and k) 0-2 wt. % of sodium hexametaphosphate, wherein the total quantity of the contents b), c), and d) equals 0.1-5 wt. %, and the total quantity of the contents e), f), g), h), i), j), and k) equals 0.01-2 wt. %.

Abstract: A multi-component packaging unit (kit of parts) for oxidatively coloring keratin fibers, including two preparations (A) and (B) packaged separate from each other. Preparation (A) includes, in a cosmetic carrier, (a1) at least one oxidation dye precursor and (a2) ammonia, and preparation (B) includes, in a cosmetic carrier, (b1) hydrogen peroxide, (b2) at least one fatty alcohol from the group comprising arachidyl alcohol (eicosan-1-ol), gadoleyl alcohol ((9Z)-eicos-9-en-1-ol), arachidonyl alcohol ((5Z,8Z,11Z,14Z)-eicosa-5,8,11,14-tetraen-1-ol), heneicosyl alcohol (heneicosan-1-ol), behenyl alcohol (docosan-1-ol), erucyl alcohol ((13Z)-docos-13-en-1-ol), and/or brassidyl alcohol ((13E)-docosen-1-ol), and (b3) at least one hydrocarbon having 8 to 80 C atoms.

Abstract: The present invention relates to a composition comprising, in a cosmetically acceptable medium, at least one water-insoluble solid organic UV-screening agent (A) at least one compound (B) that may be obtained by reaction between: an oil bearing at least one nucleophilic and/or electrophilic reactive function, and a junction group capable of establishing hydrogen bonds with one or more partner junction groups, each junction group pairing involving at least 3 hydrogen bonds, the said junction group bearing at least one reactive function capable of reacting with the reactive function borne by the oil, the said junction group also comprising at least one unit of formula (I) or (II): in which: R1 and R3, which may be identical or different, represent a divalent carbon-based radical; R2 represents a hydrogen atom or a linear, branched or cyclic, saturated or unsaturated, optionally aromatic, C1-C32 carbon-based and especially hydrocarbon-based radical, which may comprise one or more heteroatoms chosen from O, N, S,

Abstract: The present invention relates to a skin external composition, containing a Lentinula edodes-derived material, and more specifically, to an external use skin preparation composition containing an ergosterol-based compound obtained by being isolatd from a Lentinula edodes extract and purified, thereby showing remarkable whitening effects.

Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.

Abstract: The present invention relates to skin care compositions containing a small peptide mimic of TGF-? and to methods of using such compositions to manage the health and condition of skin and scalp. More preferably, the skin care compositions contain a safe and effective amount of a peptide mimic for TGF-?, derivatives of a peptide mimic for TGF-?, and mixtures thereof; a safe and effective amount of at least one skin care active; and a dermatologically acceptable carrier.

Abstract: A process for reducing hair damage upon treatment of hair by heat comprising the steps of providing a hair care composition comprising a heat-stable silicone material, applying said composition onto hair, providing a heat generating hair care appliance, and treating hair using said appliance; use and kit thereof.

Abstract: The present invention relates to a cosmetic composition which is preferentially anhydrous, comprising from 10% to 40% by weight of liquid fatty esters, at least 30% by weight of volatile oils other than the liquid fatty esters, and thickeners. The composition may also comprise particles that are insoluble in the medium, such as pigments or microcapsules. The invention also relates to a cosmetic treatment process, especially for caring for or conditioning the hair, using this composition, which is more particularly intended for curly or frizzy hair.

Abstract: Disclosed are a fermented ginseng berry Pleurotus ferulae product and a cosmetic composition containing the same. The fermented ginseng berry Pleurotus ferulae product is useful for anti-oxidation, anti-inflammation, collagen synthesis facilitation, skin wrinkle care, whitening, moisturizing, skin barrier improvement and atopy alleviation.

Abstract: The present invention relates to the use of gingival fibroblasts-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.

Abstract: An aerosolized formulation for use in a metered dose inhaler is disclosed which includes at least one active ingredient, at least one solvent, and at least one propellant. None of the at least one active ingredient, the at least one solvent and the at least one propellant include water.

Abstract: This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: The present invention relates generally to apparatuses and methods for treating ear infections and clearing excess fluid from Eustachian tubes.

Abstract: The invention provides a semi-solid chewable dosage form for use as an over-the-counter medication that contains an active pharmaceutical ingredient to treat symptoms associated with allergies, colds, coughs, fever, pain, gastrointestinal disorders, sleep, and other common conditions. The invention further provides a semi-solid chewable dosage form that contains an active pharmaceutical ingredient, a gelling agent, gelatin, sugar, a polyol, and a pH adjusting agent. The invention also provides a semi-solid chewable dosage form that contains a gelling agent, sugar, a polyol, glycerin, and a pH adjusting agent.

Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

Abstract: This invention concerns nanometric vesicles similar to liposomes (hyalurosomes) comprising molecules of hyaluronate, phospholipid molecules and at least one active pharmaceutical or cosmetic ingredient. The invention also concerns the use of hyalurosomes in topical cosmetic or pharmaceutical compositions and their preparation process.

Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.

Abstract: The present invention disclosed a method to produce a slow release lipid nanoparticles comprising steps of determining a log P value of an active ingredient; mixing fatty acid, non-ionic surfactant and the active ingredient to form a mixture; melting the mixture; homogenizing the mixture to form a nanoemulsion; sonicating the homogenized nanoemulsion; and pouring the nanoemulsion into cold water to form the liquid nanoparticles. The lipid nanoparticles with active ingredient and the selected log P value has a prolong release property. In specific embodiment, the active ingredients are the chemical compound with the log P value selected from the range 0 to 4.0.

Abstract: Embodiments described herein relate to hydrophilic matrix material and sustained drug-delivery material, and their use in medical and cosmetic applications.

Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties.

Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Abstract: The present invention relates to a preparation method for a traditional Chinese medicine drop pill and a traditional Chinese medicine micro drop pill prepared by using the method, and in particular, the present invention relates to a micro drop pill preparation method with high drug-loading capacity, simple preparation process and high production rate and a micro drop pill prepared by using the method. Specially, The drop pill preparation method used comprises the following steps: (1) material melting step: heat melting a medicine and a drop pill matrix to obtain a molten medicine liquid; (2) dropping step: delivering the molten medicine liquid to a dripper, and acquiring medicine drops of the molten medicine liquid by means of vibration dropping; and, (3) condensation step: cooling the medicine drops with a cooling gas to obtain micro drop pills.

Abstract: The invention is to provide a method for producing a soft capsule type external preparation (and a softening liquid (L) used for the production thereof, and an external preparation composed of such a capsule body (C)) which can be stably stored and leaves no film residues when rubbed with the finger when used as an external preparation although the external preparation is structured only as a capsule body (C) substantially having no external solution. An original capsule body (c) in which at least the external surface region inside an alginate capsule is present in the form of a polyvalent metal alginate is contacted with a softening liquid (L) composed of an aqueous solution comprising both “a basic amino acid (1)” and “an acid (2) selected from an organic acid or a phytic acid,” thereby impregnating the softening liquid (L) into the original capsule body (c) to obtain the capsule body (C).

Abstract: An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high. pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative.

Abstract: Disclosed herein are compositions and methods for treating or preventing the build-up or entrapment of fecal matter in the colon. The compositions and methods disclose a delayed release laxative that provides for the release of the laxative if colon-specific conditions are achieved, otherwise the laxative passes out of the body. The condition specific release of laxatives prevents harmful side effects from excessive use of non-delayed release laxatives.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: The present disclosure generally relates to suspensions and compositions of polymeric nanoparticles that include docetaxel, as well as methods of treating various cancers, including refractory or drug resistant cancers in patients in need thereof using disclosed compositions.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: The present invention relates to a safe, dermatologically safe device in the form of tape containing far-infrared generating particles and a method for producing such a product. The method for producing the far-infrared tape consists of mixing fine particles of far-infrared emitting substances into an adhesive or the tape backing material prior to or following further processing such as, but not limited to forming, molding, filling, pressing, dipping or extruding the material. The substances generating far-infrared radiation are to consist of safe substances such as, but not limited to, Magnesium, Manganese, Germanium, Iron, Zinc, Copper, Tourmaline, Silicone Dioxide, Aluminum Dioxide, Germanium, Iron Oxide, Calcium Carbonate or mixture thereof. Other ingredients can be included to further add to the health benefits of this invention.

Abstract: The present invention relates generally to methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. The invention also relates to methods of treating or preventing Alzheimer's disease or MCI that involve the use of such compositions. The invention further provides methods to promote the general health of the nervous system through administration of active ingredient compositions. The invention further relates to animal and cellular systems for the study of AD, MCI, and related disorders, and the identification of reagents useful in treating amyloidosis. The invention further provides methods to inhibit AD or MCI in an individual based on reducing caloric intake by the individual.

Abstract: This invention is related to dermal matrices and production method thereof, having within its structure micro particles having antioxidant agents with synergistic effects, providing speedy repair of the dermal tissue, used in chronic wound treatments, basically comprising the steps of preparing the dermal matrix system (11), forming micro particles (12), combining the micro particles with the dermal matrix system.

Abstract: Compositions contain a therapeutically effective amount of tiglic aldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing glycemia by improving insulin sensitivity improving mood, memory or cognition. Methods are provided that include administering such compositions.

Abstract: Compositions contain a therapeutically effective amount of cuminaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing gylcemia by improving insulin sensitivity or improving mood, memory or cognition. Methods are provided that include administering such compositions.

Abstract: Disclosed herein is a solution that makes use of a food product that is effective for the detrimental decline of energy metabolism in humans and other mammals in need of treatment and/or prevention of accelerated energy expenditure and/or diminished energy expenditure functionality. The method disclosed herein continuously administers a functional food product rare sugar containing at least D-psicose to effectively improve energy expenditure.

Abstract: A dietary supplement composition to treat low density lipoprotein (LDL) oxidation in humans includes a therapeutic amount of a phospholipid rich egg roe extract having at least 50 percent phospholipids and a seed oil extract in combination with astaxanthin in an oral dosage form. The astaxanthin is 0.1 to 15 percent by weight of the at least phospholipid rich egg roe extract.

Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Abstract: The invention is directed to the use of a compound of formula I as defined herein, a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing a compound of formula I, in treating a mammal, including a human, for a psychiatric disorder or condition selected from the group consisting of stroke, Huntington's disease and amyotrophic lateral sclerosis (ALS).

Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Abstract: A method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N?-di-1-Naphthylguanidine hydrochloride (NAGH); N,N?-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts. Both NAD and NAGH, when administered 24 hours after experimental stroke, reduced neural damage and enhanced behavioral recovery thirty days later which suggests that NAGH and NAD potentially extend the therapeutic window of stroke several fold over the current treatments.

Abstract: Novel polyamine transport inhibitors have been synthesized and demonstrated to block the uptake of native polyamines into human cancer cells. A combination therapy of the transport inhibitor and DFMO (a drug which blocks polyamine biosynthesis) provided synergistic activity against a metastatic human colon cancer cell line. The strategy uses polyamine depletion and polyamine metabolism to generate reactive oxygen species within cells as a novel way to treat cancers. This approach may be implemented for widespread use in the treatment of diseases which rely upon polyamine transport activity for proliferation.